VRN-11 is under clinical development by Voronoi Group and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how VRN-11’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VRN-11 overview

VRN-11 is under development for the treatment of non-small cell lung cancer. The therapeutic candidate acts by targeting C797S mutant epidermal growth factor receptor (EGFR) and is administered orally as capsules. It is being developed based on voronomics platform.

Voronoi Group overview

Voronoi Group (Voronoi) develops new drugs for the treatment of rare and intractable diseases. The company carries out the development of target protein degraders (TPDs) and kinase inhibitors. Its pipeline includes VRN01, VRN06, VRN07, VRN08, VRN09 and others .Voronoi is involved in the technology transfer of new drug candidates prior to electroclinical clinical trials by using AI platform integrating molecular model and structural biology. The company operates in Korea. Voronoi is headquartred in Yeonsu-gu, Incheon, Republic of Korea.

For a complete picture of VRN-11’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.